Form 4: Tempest Therapeutics Corporate Controller Acquires 30,000 Stock Options

Tempest Therapeutics' Corporate Controller, Justin Trojanowski, was granted 30,000 stock options on January 2, 2025, according to a recent SEC filing.

Summary

• Justin Trojanowski, the Corporate Controller of Tempest Therapeutics, Inc., was granted 30,000 employee stock options.
• The options have an exercise price of $0.86 per share.
• The options vest in 48 equal monthly installments starting from January 2, 2025, contingent upon continued service.
• The options expire on January 1, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of equity compensation, which is generally positive for employee retention and alignment of interests. There are no indications of negative news or concerns.

Positives

• The granting of stock options aligns the interests of the Corporate Controller with the company's performance.
• The vesting schedule encourages long-term commitment from the employee.

Risks

• The value of the options is dependent on the future performance of Tempest Therapeutics' stock price.
• If the stock price does not increase above the exercise price, the options may not be valuable to the employee.

Future Outlook

The vesting of the stock options is contingent on the continued service of the Corporate Controller, suggesting a focus on retaining key personnel.

Industry Context

Stock option grants are a common form of compensation for executives and key employees in the biotechnology industry, aligning their interests with the company's long-term success.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry, often used to attract and retain talent.
• Vesting schedules, such as the 48-month monthly vesting in this case, are typical to ensure long-term commitment.
• The exercise price of $0.86 is specific to Tempest Therapeutics' stock and its current valuation.

Stakeholder Impact

• The stock option grant may positively impact employee morale and retention.
• Shareholders may view this as a positive sign of aligning management's interests with the company's long-term performance.

Key Dates

Keywords

stock options, insider trading, SEC Form 4, Tempest Therapeutics, equity compensation, corporate controller